在猫科动物中，眼部和非眼部黑色素瘤是罕见的肿瘤，这对病理学家来说是一个诊断挑战，尤其是无黑色素瘤时。迄今为止，猫的免疫组织化学诊断组合基于特异性黑素细胞标记（Melan-A 和 PNL2）和非特异性但敏感的标记（S100）。在人类医学中，SOX-10 据报道是一种用于检测淋巴结中黑色素瘤微转移的敏感抗体。 TRP-1 是一种参与黑色素生成的酶，最近已被用作人类和狗的特定黑色素细胞标记物。本研究的目的是评估猫正常组织和黑素细胞肿瘤中 SOX-10 和 TRP-1 抗体的交叉反应性和表达。通过组织病理学检查和 Melan-A 和/或 PNL2 免疫标记对 31 例眼部、皮肤和口腔黑色素瘤进行回顾性评估和确诊。正常组织中SOX-10核表达位于表皮、表皮下、毛球、虹膜基质黑素细胞和真皮神经中。在黑色素瘤中，在眼部（11/12；92%）、口腔（6/7；86%）和皮肤部位（12/12；100%）检测到 SOX-10 的核表达。在正常组织的表皮和球部黑素细胞以及虹膜内层色素上皮及其基质中观察到 TRP-1 细胞质免疫标记。其表达与肿瘤色素沉着程度呈正相关，在 75% 的眼部黑色素瘤 (9/12)、43% 的口腔黑色素瘤 (3/7) 和 33% 的皮肤黑色素瘤 (4/12) 中观察到。这项研究证明了 SOX-10 和 TRP-1 抗体在猫非肿瘤性黑色素细胞中的交叉反应性及其在眼部和非眼部黑色素瘤中的表达。

In felines, ocular and nonocular melanomas are uncommon tumors that represent a diagnostic challenge for pathologists, especially when amelanotic. To date, the immunohistochemical diagnostic panel in cats is based on specific melanocytic markers (Melan-A and PNL2) and a nonspecific but sensitive marker (S100). In human medicine, SOX-10 is reported to be a sensitive antibody for the detection of melanoma micrometastasis in the lymph node. TRP-1, an enzyme involved in melanogenesis, has recently been used in humans and dogs as a specific melanocyte marker. The aim of this study was to evaluate the cross-reactivity and the expression of SOX-10 and TRP-1 antibodies in feline normal tissue and melanocytic tumors. Thirty-one cases of ocular, cutaneous, and oral melanomas were retrospectively evaluated and confirmed by histopathological examination and by immunolabeling with Melan-A and/or PNL2. SOX-10 nuclear expression in normal tissues was localized in epidermal, subepidermal, hair bulb, and iridal stromal melanocytes and dermal nerves. In melanomas, nuclear expression of SOX-10 was detected in ocular (11/12; 92%), oral (6/7; 86%), and cutaneous sites (12/12; 100%). TRP-1 cytoplasmic immunolabeling in normal tissue was observed in epidermal and bulbar melanocytes and in the lining pigmented epithelium of the iris and in its stroma. Its expression was positively correlated to the degree of pigmentation in the tumor and was observed in 75% of ocular (9/12), 43% of oral (3/7), and 33% of cutaneous melanomas (4/12). This study demonstrated the cross-reactivity of SOX-10 and TRP-1 antibodies in feline non-neoplastic melanocytes and their expression in ocular and nonocular melanomas.